Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Akari Therapeutics PlcAKTX · Entity 7692 | Interim CFO | August 17, 2026 | August 19, 2026 |
| BIOVIE INC.BIVI · Entity 7702 | Director | January 05, 2026 | January 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Akari Therapeutics Plc
Report date August 17, 2026 · Filed August 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary Shares representing Ordinary SharesSEC Table I · non-derivative | Direct | 23,309 |
Reported balance
After 2026-08-17 transaction · row 1
1 source rowRow 1 · 2026-08-17 · Grant · Acquired 1,728 · Balance 23,309 F1: These American Depositary Shares represent restricted stock units ("RSUs"), with each such RSU representing the right to receive 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. The RSUs will vest in full on September 15, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: These American Depositary Shares represent restricted stock units ("RSUs"), with each such RSU representing the right to receive 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. The RSUs will vest in full on September 15, 2026.
BIOVIE INC.
Report date January 05, 2026 · Filed January 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.31 · Expires 2031-01-05 | Direct | 57,500 |
Reported balance
After 2026-01-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-05 · Grant · Acquired 57,500 · Balance 57,500 F1: 7,500 shares of the underlying options vest s on grant date and the remaining balance in four equal installments on February 11, 2026, May 11, 2026, August 11, 2026 and the earlier of November 11, 2026 and the date of the registrant's 2026 annual shareholders' meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: 7,500 shares of the underlying options vest s on grant date and the remaining balance in four equal installments on February 11, 2026, May 11, 2026, August 11, 2026 and the earlier of November 11, 2026 and the date of the registrant's 2026 annual shareholders' meeting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 17, 2026 Filed Aug 19, 2026 21:00 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantAmerican Depositary Shares representing Ordinary Shares | 1,728 | $7.52 | $12,994.56 |
DisclosureSEC source: 0001493152-26-039246 · ownership.xml · nonDerivative · entry 1 Farag Kameel D. · CIK 0002093620 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,309 F1 · shares: These American Depositary Shares represent restricted stock units ("RSUs"), with each such RSU representing the right to receive 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. The RSUs will vest in full on September 15, 2026. Read SEC document |
| July 16, 2026 Filed Aug 5, 2026 22:30 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantAmerican Depositary Shares representing Ordinary Shares | 1,130 | $11.50 | $12,995.00 |
DisclosureSEC source: 0001493152-26-036231 · ownership.xml · nonDerivative · entry 1 Farag Kameel D. · CIK 0002093620 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,581 F1 · shares: These American Depositary Shares represent restricted stock units ("RSUs"), with each such RSU representing the right to receive 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. The RSUs will vest in full on August 16, 2026. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 00:06 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantAmerican Depositary Shares representing Ordinary Shares | 1,000 | $13.00 | $13,000.00 |
DisclosureSEC source: 0001493152-26-030210 · ownership.xml · nonDerivative · entry 7 Farag Kameel D. · CIK 0002093620 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,452 F1 · shares: These American Depositary Shares represent restricted stock units ("RSUs"), with each such RSU representing the right to receive 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. The RSUs vested in full on June 24, 2026. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 00:06 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantAmerican Depositary Shares representing Ordinary Shares | 7,353 | $3.74 | $27,500.22 |
DisclosureSEC source: 0001493152-26-030210 · ownership.xml · nonDerivative · entry 6 Farag Kameel D. · CIK 0002093620 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,452 F1 · shares: These American Depositary Shares represent restricted stock units ("RSUs"), with each such RSU representing the right to receive 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. The RSUs vested in full on June 24, 2026. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 00:06 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantAmerican Depositary Shares representing Ordinary Shares | 3,725 | $3.49 | $13,000.25 |
DisclosureSEC source: 0001493152-26-030210 · ownership.xml · nonDerivative · entry 5 Farag Kameel D. · CIK 0002093620 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,099 F1 · shares: These American Depositary Shares represent restricted stock units ("RSUs"), with each such RSU representing the right to receive 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. The RSUs vested in full on June 24, 2026. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 00:06 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantAmerican Depositary Shares representing Ordinary Shares | 2,539 | $5.12 | $12,999.68 |
DisclosureSEC source: 0001493152-26-030210 · ownership.xml · nonDerivative · entry 4 Farag Kameel D. · CIK 0002093620 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,374 F1 · shares: These American Depositary Shares represent restricted stock units ("RSUs"), with each such RSU representing the right to receive 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. The RSUs vested in full on June 24, 2026. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 00:06 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantAmerican Depositary Shares representing Ordinary Shares | 1,570 | $8.28 | $12,999.60 |
DisclosureSEC source: 0001493152-26-030210 · ownership.xml · nonDerivative · entry 3 Farag Kameel D. · CIK 0002093620 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,835 F1 · shares: These American Depositary Shares represent restricted stock units ("RSUs"), with each such RSU representing the right to receive 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. The RSUs vested in full on June 24, 2026. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 00:06 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantAmerican Depositary Shares representing Ordinary Shares | 1,395 | $9.32 | $13,001.40 |
DisclosureSEC source: 0001493152-26-030210 · ownership.xml · nonDerivative · entry 2 Farag Kameel D. · CIK 0002093620 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,265 F1 · shares: These American Depositary Shares represent restricted stock units ("RSUs"), with each such RSU representing the right to receive 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. The RSUs vested in full on June 24, 2026. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 00:06 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantAmerican Depositary Shares representing Ordinary Shares | 1,248 | $10.02 | $12,504.96 |
DisclosureSEC source: 0001493152-26-030210 · ownership.xml · nonDerivative · entry 1 Farag Kameel D. · CIK 0002093620 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,870 F1 · shares: These American Depositary Shares represent restricted stock units ("RSUs"), with each such RSU representing the right to receive 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. The RSUs vested in full on June 24, 2026. Read SEC document |
| January 05, 2026 Filed Jan 9, 2026 22:01 UTC | BIOVIE INC. BIVI · Entity 7702 | GrantStock Option (right to buy) · Derivative | 57,500 | $0.00 Strike: $1.31 | $0.00 |
DisclosureSEC source: 0001520138-26-000019 · ownership.xml · derivative · entry 1 Farag Kameel D. · CIK 0002093620 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,500 Underlying: COMMON STOCK · 57,500 shares Expires 2031-01-05 F1 · derivative.exercise_date: 7,500 shares of the underlying options vest s on grant date and the remaining balance in four equal installments on February 11, 2026, May 11, 2026, August 11, 2026 and the earlier of November 11, 2026 and the date of the registrant's 2026 annual shareholders' meeting. Read SEC document |
| December 16, 2025 Filed Dec 19, 2025 02:57 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | PurchasePre-Funded Warrants to purchase ADRs · Derivative | 24,745 | $0.40 Strike: $0.00 | $9,999.45 |
DisclosureSEC source: 0001493152-25-028419 · ownership.xml · derivative · entry 2 Farag Kameel D. · CIK 0002093620 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,745 Underlying: American Depositary Shares representing Ordinary Shares · 24,745 shares Expires not disclosed F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer. F2 · security: On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 24,745 ADSs (the "PIPE PFWs" and ) and (ii) accompanying Series G Warrants to purchase up to 24,745 ADSs (the "Series G Warrants"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended. F5 · derivative.exercise_price: Conversion Exercise Price of Security is $0.00001 F4 · price: The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041. F3 · derivative.exercise_date: The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the Private Placement Unregistered Warrants remaining exercisable until fully exercised. F3 · derivative.expiration_date: The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the Private Placement Unregistered Warrants remaining exercisable until fully exercised. Read SEC document |
| December 16, 2025 Filed Dec 19, 2025 02:57 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | PurchaseWarrants to purchase American Depositary Shares ("ADRs") · Derivative | 24,745 | Not disclosed Strike: $0.39 | Not disclosed |
DisclosureSEC source: 0001493152-25-028419 · ownership.xml · derivative · entry 1 Farag Kameel D. · CIK 0002093620 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,745 Underlying: American Depositary Shares representing Ordinary Shares · 24,745 shares Expires not disclosed F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer. F2 · security: On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 24,745 ADSs (the "PIPE PFWs" and ) and (ii) accompanying Series G Warrants to purchase up to 24,745 ADSs (the "Series G Warrants"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended. F4 · price: The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041. F3 · derivative.exercise_date: The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the Private Placement Unregistered Warrants remaining exercisable until fully exercised. F3 · derivative.expiration_date: The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the Private Placement Unregistered Warrants remaining exercisable until fully exercised. Read SEC document |
| November 01, 2025 Filed Nov 4, 2025 22:00 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantAmerican Depositary Shares representing Ordinary Shares | 26,619 | $0.75 | $19,964.25 |
DisclosureSEC source: 0001493152-25-020753 · ownership.xml · nonDerivative · entry 2 Farag Kameel D. · CIK 0002093620 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,619 F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer F3 · shares: These ADSs represent restricted stock units ("RSUs"), with each such RSU representing the right to receive 2,000 Ordinary Shares par value $0.0001. The RSUs shall vest on February 15, 2026. Read SEC document |
| November 01, 2025 Filed Nov 4, 2025 22:00 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantAmerican Depositary Shares representing Ordinary Shares | 32,000 | $0.75 | $24,000.00 |
DisclosureSEC source: 0001493152-25-020753 · ownership.xml · nonDerivative · entry 1 Farag Kameel D. · CIK 0002093620 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,000 F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer F2 · shares: These ADSs represent restricted stock units ("RSUs"), with each such RSU representing the right to receive 2,000 Ordinary Shares par value $0.0001. The RSUs shall vest on January 1, 2026. Read SEC document |
| October 22, 2025 Filed Oct 24, 2025 13:18 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantAmerican Depositary Shares representing Ordinary Shares | 6,277 | $0.74 | $4,644.98 |
DisclosureSEC source: 0001493152-25-019194 · ownership.xml · nonDerivative · entry 1 Farag Kameel D. · CIK 0002093620 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,277 F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer F2 · shares: These ADSs represent restricted stock units ("RSUs"), with each such RSU representing the right to receive 2,000 Ordinary Shares par value $0.0001. The RSUs shall vest on October 31, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.